Trivanović Drenka, Krstić Jelena, Djordjević Ivana Okić, Mojsilović Slavko, Santibanez Juan Francisco, Bugarski Diana, Jauković Aleksandra
Laboratory for Experimental Hematology and Stem Cells, Institute for Medical Research, University of Belgrade, Dr. Subotića 4, P.O. Box 102, 11129 Belgrade, Serbia.
Laboratory for Experimental Hematology and Stem Cells, Institute for Medical Research, University of Belgrade, Dr. Subotića 4, P.O. Box 102, 11129 Belgrade, Serbia; Laboratorio de Bionanotecnologia, Universidad Bernardo O Higgins, General Gana 1780, 8370854 Santiago, Chile.
Mediators Inflamm. 2016;2016:7314016. doi: 10.1155/2016/7314016. Epub 2016 Aug 18.
State of tumor microenvironment (TME) is closely linked to regulation of tumor growth and progression affecting the final outcome, refractoriness, and relapse of disease. Interactions of tumor, immune, and mesenchymal stromal/stem cells (MSCs) have been recognized as crucial for understanding tumorigenesis. Due to their outstanding features, stem cell-like properties, capacity to regulate immune response, and dynamic functional phenotype dependent on microenvironmental stimuli, MSCs have been perceived as important players in TME. Signals provided by tumor-associated chronic inflammation educate MSCs to alter their phenotype and immunomodulatory potential in favor of tumor-biased state of MSCs. Adjustment of phenotype to TME and acquisition of tumor-promoting ability by MSCs help tumor cells in maintenance of permissive TME and suppression of antitumor immune response. Potential utilization of MSCs in treatment of tumor is based on their inherent ability to home tumor tissue that makes them suitable delivery vehicles for immune-stimulating factors and vectors for targeted antitumor therapy. Here, we review data regarding intrusive effects of inflammatory TME on MSCs capacity to affect tumor development through modification of their phenotype and interactions with immune system.
Adv Exp Med Biol. 2016
Semin Immunol. 2017-12-27
Curr Stem Cell Res Ther. 2019
Mol Cancer. 2017-2-1
Adv Exp Med Biol. 2020
Front Immunol. 2024
NPJ Syst Biol Appl. 2023-12-12
Front Cell Dev Biol. 2023-10-2
Int J Bioprint. 2022-8-16
Bioengineering (Basel). 2022-11-5
World J Stem Cells. 2016-3-26
Mediators Inflamm. 2016
Stem Cells Int. 2016
Cancer Immunol Immunother. 2016-2